LRRK2 as a target for modulating immune system responses
Authors:
Open Access
- 12 April 2022
- journal article
- research article
- Published by Elsevier in Neurobiology of Disease
- Vol. 169, 105724
Abstract
No abstract availableKeywords
This publication has 105 references indexed in Scilit:
- LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat proteinJournal of Neuroinflammation, 2012
- The IkappaB Kinase Family Phosphorylates the Parkinson’s Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor SignalingPLOS ONE, 2012
- LRRK2 Inhibition Attenuates Microglial Inflammatory ResponsesThe Journal of Neuroscience, 2012
- Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structuresJournal of Neural Transmission, 2011
- LRRK2 Is Involved in the IFN-γ Response and Host Response to PathogensThe Journal of Immunology, 2010
- The G2019S pathogenic mutation disrupts sensitivity of leucine‐rich repeat kinase 2 to manganese kinase inhibitionJournal of Neurochemistry, 2010
- 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localizationBiochemical Journal, 2010
- Anti-inflammatory drugs and risk of Parkinson diseaseNeurology, 2010
- Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synucleinNeuron, 2009
- Expression and localization of Parkinson's disease‐associated leucine‐rich repeat kinase 2 in the mouse brainJournal of Neurochemistry, 2006